Abiopharma

🔍 McBee Brannin (Executive)

Company: CoreWeave, Inc. (CRWV)

Report Date: 2026-08-24

Detailed Transactions and Holdings:

• Sold 97 shares of Class A Common Stock at $83.9506 per share (Direct)
  Date: 2026-08-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 48,403.00 | transaction_form_type: 4 | Footnotes: F1, F2, F3
• Sold 75 shares of Class A Common Stock at $84.6781 per share (Direct)
  Date: 2026-08-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 48,328.00 | transaction_form_type: 4 | Footnotes: F1, F4, F3
• Sold 243 shares of Class A Common Stock at $86.0297 per share (Direct)
  Date: 2026-08-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 48,085.00 | transaction_form_type: 4 | Footnotes: F1, F5, F3
• Sold 85 shares of Class A Common Stock at $86.5479 per share (Direct)
  Date: 2026-08-24 | Code: S | equity_swap_involved: 0 | shares_owned_after: 48,000.00 | transaction_form_type: 4 | Footnotes: F1, F6, F3
• Holds 0 shares of Class A Common Stock (Direct)
  Date: 2026-08-24 | Code: H | nature_of_ownership: See Footnote | shares_owned_after: 1,800.00 | Footnotes: F7
• Holds 108,600 shares of Class B Common Stock (Derivative)
  Date: 2026-08-24 | Code: H | shares_owned_after: 108,600.00 | Footnotes: F8, F8, F8, F9
• Holds 1,582,773 shares of Class B Common Stock (Derivative)
  Date: 2026-08-24 | Code: H | shares_owned_after: 1,582,773.00 | Footnotes: F8, F8, F8, F10
• Holds 122,000 shares of Class B Common Stock (Derivative)
  Date: 2026-08-24 | Code: H | shares_owned_after: 122,000.00 | Footnotes: F8, F8, F8, F11
• Holds 263,795 shares of Class B Common Stock (Derivative)
  Date: 2026-08-24 | Code: H | shares_owned_after: 263,795.00 | Footnotes: F8, F8, F8, F12

Footnotes:

• F1: The reported transaction represents a sale effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 5, 2026.
• F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.31 to $84.30, inclusive.
• F3: The reported securities are directly held by the Canis Major SM Trust (the "Canis Trust"), an irrevocable trust with a third-party trustee, of which the reporting person's minor child is beneficiary. The reporting person has the power to remove and replace the Canis Trust's trustee.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.31 to $85.30, inclusive.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.35 to $86.34, inclusive.
• F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.35 to $86.94, inclusive.
• F7: The reported securities are directly held of record by the reporting person's child.
• F8: Each share of Class B Common Stock is convertible into one share of the Issuer's Class A Common Stock at any time, at the election of the holder or automatically upon certain transfers, whether or not for value, or upon the occurrence of certain events or conditions described in the Issuer's Amended and Restated Certificate of Incorporation.
• F9: The reported securities are directly held by the Canis Major 2025 Family Trust LLC, of which the reporting person serves as manager.
• F10: The reported securities are directly held by a grantor retained annuity trust, of which the reporting person is the sole trustee and beneficiary.
• F11: The reported securities are directly held by the Canis Minor 2025 Family Trust LLC, of which the reporting person serves as manager.
• F12: The reported securities are directly held by a grantor retained annuity trust, of which the reporting person's spouse is the sole beneficiary and trustee.
• REMARKS: This Form 4 is Part 2 of 2 for this reporting person. Transactions by the reporting person are continued on this Part 2.